Maintaining Weight Loss With GLP-1 Tablets After Injectable Treatment

GLP-1 tablets may help some people maintain weight loss after injections by continuing to support appetite control without the need for weekly injections.

This could be helpful for people who:

• have reached their weight loss goal on injectable treatment
• want to avoid long-term injections
• are struggling with injection fatigue
• want a more convenient maintenance option
• need ongoing appetite support to reduce weight regain
• However, not all GLP-1 tablets have the same level of evidence for post-injection maintenance.

The strongest current evidence comes from the ATTAIN-MAINTAIN study, which looked at orforglipron after previous injectable treatment.

The ATTAIN-MAINTAIN trial studied whether oral orforglipron could help people keep weight off after they had already lost weight on injectable treatment.

The study included 376 adults who had previously completed 72 weeks of injectable treatment.

One group had previously used Mounjaro, and the other had previously used Wegovy injections.

Participants were then switched to either once-daily oral orforglipron or placebo for 52 weeks.

This makes the study particularly relevant because it directly tested a practical question:

Can a GLP-1 tablet help people maintain weight loss after stopping injectable treatment?

The results showed that people who switched to orforglipron maintained much more of their previous weight loss than people switched to placebo.

This means that people who switched to orforglipron maintained 75% of their weight loss, while those switched to placebo regained more weight.  

The study also looked at how many people maintained at least 80% of the weight they had already lost.

This means people taking orforglipron were much more likely to maintain the majority of their previous weight loss than those who stopped active treatment.

If someone lost 20kg on injectable treatment, maintaining:

• 75% would mean keeping off around 15kg
• 50% would mean keeping off around 10kg
• 38% would mean keeping off around 7.6kg

So, in practical terms, orforglipron may help reduce the amount of weight regained after stopping injectable treatment.

It does not mean everyone will maintain all of their weight loss, but the trial suggests that continuing with an oral GLP-1 can help preserve more weight loss than stopping active treatment completely.

Based on ATTAIN-MAINTAIN, yes. People who switched to orforglipron maintained significantly more of their previous weight loss than people who switched to placebo.

This supports the idea that weight loss treatment may need a long-term maintenance phase, similar to how blood pressure or cholesterol treatment is often continued long term.

The study does not prove that orforglipron is better than staying on injectable treatment. It compared switching to orforglipron against switching to placebo after previous injectable treatment.

GLP-1 tablets could become useful for maintenance because they may be easier to take long term than injections.

Potential benefits include:

• no injections
• daily oral dosing
• easier storage and transport
• potentially easier long-term adherence
• useful for people with injection fatigue
• possible step-down option after reaching a target weight

For some people, the goal may not be to keep losing large amounts of weight. Instead, the goal may be to maintain the weight already lost and prevent regain.

The ATTAIN-MAINTAIN study used the investigational orforglipron capsule formulation, up to 36mg or the maximum tolerated dose.

The paper states that these capsule doses correspond to tablet doses, with the 36mg capsule broadly corresponding to the 17.2mg tablet dose.

A simple way to explain this is:

Earlier orforglipron trials used capsules, while the approved product uses tablets with different dose labels. The highest trial dose, 36mg, is considered broadly equivalent to the highest tablet dose, 17.2mg, because both provide similar drug exposure in the body.

Further reading: Orforglipron dosage guide

At present, there does not appear to be a dedicated maintenance study showing that Wegovy tablets help people keep weight off after switching from injectable Wegovy or Mounjaro.

The OASIS trials show that oral semaglutide can produce meaningful weight loss while treatment continues, but they were not designed specifically as post-injection maintenance studies.

This makes orforglipron’s ATTAIN-MAINTAIN data important, because it directly studied oral GLP-1 treatment as a maintenance option after injectable treatment.

Medication can help, but long-term weight maintenance also depends on habits and follow-up support.

Keep protein intake high

During weight loss, eating enough protein can help preserve muscle and keep you fuller for longer.

Strength train where possible

Resistance training helps maintain muscle mass, which is important for metabolism, strength and long-term body composition.

Monitor your weight regularly

Checking your weight weekly can help you catch regain early, before it becomes harder to reverse.

Maintain a structured eating pattern

Skipping meals, grazing, or returning to previous portion sizes can make weight regain more likely.

Have a maintenance plan before stopping injections

The best time to plan maintenance is before stopping injectable treatment, not after weight regain has already started.

Consider ongoing treatment where appropriate

Some people may need ongoing medication to maintain weight loss. This should always be discussed with a qualified prescriber.

Maintaining weight loss after injectable GLP-1 treatment can be challenging because appetite often returns when treatment stops.

The ATTAIN-MAINTAIN trial suggests that switching to once-daily oral orforglipron may help people keep more weight off after previous treatment with injectable tirzepatide or semaglutide.

In the study, people taking orforglipron maintained around three-quarters or more of their previous weight loss over 52 weeks, while those switched to placebo regained more weight.

This makes orforglipron one of the first oral GLP-1 treatments with specific evidence for maintaining weight loss after injectable treatment.